Browse > Article
http://dx.doi.org/10.13160/ricns.2017.10.4.202

Hologram Based QSAR Analysis of Xanthine Oxidase Inhibitors  

Sathya., B (Department of Genetic Engineering, School of Bioengineering, SRM University)
Publication Information
Journal of Integrative Natural Science / v.10, no.4, 2017 , pp. 202-208 More about this Journal
Abstract
Xanthine Oxidase is an enzyme, which oxidizes hypoxanthine to xanthine, and xanthine to uric acid. It is widely distributed throughout various organs including the liver, gut, lungs, kidney, heart, brain and plasma. It is involved in gout pathogenesis. Hence, in the present study, Hologram based Quantitative Structure Activity Relationship Study was performed on a series of Xanthine Oxidase antagonist named 2-(indol-5-yl) thiazole derivatives. The best HQSAR model was obtained using Atoms, Bonds, Connection, Hydrogen, Chirality and Donor Acceptor as fragment distinction parameter using hologram length 71 and 4 components with fragment size of minimum 2 and maximum 5. Significant cross-validated correlation coefficient ($q^2$= 0.563) and non cross-validated correlation coefficients ($r^2$= 0.967) were obtained. The model was then used to evaluate the six external test compounds and its $r^2{_{pred}}$ was found to be 0.798. Contribution map show that presence of propyl ring in indole thiazole makes big contributions for improving the biological activities of the compounds. We hope that our HQSAR model and analysis will be helpful for future design of xanthine oxidase antagonists.
Keywords
Xanthine Oxidase; HQSAR;
Citations & Related Records
연도 인용수 순위
  • Reference
1 B. L. Love, R. Barrons, A. Veverka, and K. M. Snider, "Urate-lowering therapy for gout: focus on febuxostat", Pharmacotherapy, Vol. 30, pp. 594-608, 2010.   DOI
2 Tripos Sybyl, HQSAR manual.
3 D. A. Parks and D. N. Granger, "Xanthine oxidase: biochemistry, distribution and physiology", Acta Physiol. Scand. Suppl., Vol. 548, pp. 87-99, 1986.
4 C. L. Waller, "A comparative QSAR study using CoMFA, HQSAR, and FRED/SKEYS paradigms for estrogen receptor binding affinities of structurally diverse compounds", J. Chem. Inf. Model., Vol. 44, pp. 758-765, 2004.
5 W. Tong, D. R. Lowis, R. Perkins, Y. Chen, W. J. Welsh, D. W. Goddette, T. W. Heritage, and D. M. Sheehan, "Evaluation of quantitative structure- activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor", J. Chem. Inf. Model., Vol. 38, pp. 669-677, 1998.
6 T. W Heritage and D. R. Lowis, "Molecular Hologram QSAR", In Rational Drug Design: Novel methodology and Practical Application, eds. A. L. Parrill, M. R. Reddy, Washington: America Chemical Society, Symposium Series, Vol. 719, pp. 212- 225, 1999.
7 J. U. Song, S. P Choi, T. H. Kim, C.-K. Jung, J.- Y. Lee, S.-H. Jung, and G. T. Kim, "Design and synthesis of novel 2-(indol-5-yl)thiazole derivatives as xanthine oxidase inhibitors", Bioorg. Med. Chem. Lett., Vol. 25, pp. 1254-1258, 2015.   DOI
8 D. A Winker and F. R. Burden, "Holographic QSAR of benzodiazepines", Mol. Inform., Vol. 17, pp. 224- 231, 1998.
9 S. Wold, "Cross-validatory estimation of the number of components in factor and principal component model", Technometrics, Vol. 20, pp. 397-405, 1978.   DOI
10 P. Pacher, A. Nivorozhkin, and C. Szabo, "Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol", Pharmacol. Rev., Vol. 58, pp. 87-114, 2006.   DOI
11 M. Cicoira, L. Zanolla, A. Rossi, G. Golia, L. Franceschini, G. Brighetti, P. Zeni, and P. Zardini, "Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy", Am. Heart. J., Vol. 143, pp. 1107-1111, 2002.   DOI
12 K. D, Pfeffer, T. P. Huecksteadt, and J. R. Hoidal, "Xanthine dehydrogenase and xanthine oxidase activity and gene expression in renal epithelial cells. Cytokine and steroid regulation", J. Immunol., Vol. 153, pp. 1789-1797, 1994.
13 H. M. Kramer and G. Curhan, "The association between gout and nephrolithiasis: the national health and nutrition examination survey III, 1988-1994", Am. J. Kidney Dis., Vol. 40, pp. 37-42, 2002.   DOI
14 R. L. Wortmann, "Recent advances in the management of gout and hyperuricemia", Curr. Opin. Rheumatol., Vol. 17, pp. 319-324, 2005.   DOI
15 J. George and A. D. Struthers, "The role of urate and xanthine oxidase inhibitors in cardiovascular disease", Cardiovasc. Ther., Vol. 26, pp. 59-64, 2008.
16 N. Dalbeth and L. Stamp, "Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events", Semin. Dial., Vol. 20, pp. 391-395, 2007.   DOI
17 T.-F. Tsai and T.-Y. Yeh, "Allopurinol in dermatology", Am. J. Clin. Dermatol., Vol. 11, pp. 225-232, 2010.   DOI